Meeder Advisory Services’s Royalty Pharma RPRX Stock Holding History

Meeder Advisory Services’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$909K	Buy	18,948 +517	+3%	+$22.6K	0.04%	295
2025 Q4	$712K	Buy	18,431 +1,353	+8%	+$51.6K	0.03%	336
2025 Q3	$603K	Sell	17,078 -181	-1%	-$6.55K	0.03%	354
2025 Q2	$622K	Buy	17,259 +4,853	+39%	+$161K	0.03%	337
2025 Q1	$386K	Buy	12,406 +995	+9%	+$31.5K	0.02%	406
2024 Q4	$291K	Buy	11,411 +4,201	+58%	+$111K	0.02%	459
2024 Q3	$204K	Sell	7,210 -1,013	-12%	-$28.1K	0.01%	526
2024 Q2	$217K	Buy	8,223 +926	+13%	+$25.7K	0.02%	476
2024 Q1	$222K	Sell	7,297 -185	-2%	-$5.45K	0.02%	411
2023 Q4	$210K	Buy	+7,482	New	+$206K	0.02%	405

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Meeder Advisory Services's RPRX Position: Q1 2026 in Review

Meeder Advisory Services increased its Royalty Pharma (RPRX) stake by 2.8% in Q1 2026, buying an estimated $22.6K and bringing the position to 18,948 shares worth $909K. The position accounts for 0.04% of the portfolio, ranked #295.

Meeder Advisory Services first reported a position in RPRX in Q4 2023 and has held it in 10 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Meeder Advisory Services held 18,948 shares of Royalty Pharma worth $909K as of Q1 2026.
Meeder Advisory Services bought 517 Royalty Pharma shares in Q1 2026, an estimated $22.6K.
Royalty Pharma made up 0.04% of Meeder Advisory Services's portfolio in Q1 2026, its #295 holding.
Meeder Advisory Services first reported a position in Royalty Pharma in Q4 2023 and has held it in 10 quarters since.
587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Meeder Advisory Services's 13F filing for Q1 2026, filed 7 May 2026.